Gene Therapy
Page 1 • 9 itemsUnlock global gene therapy market insights. Stay ahead on regulatory approvals, clinical trials, and investment opportunities in this cutting-edge biotech sector.
Arrowhead Pharmaceuticals Receives TGA Approval for REDEMPLO (Plozasiran) in Australia for Rare Genetic Disorder
Arrowhead Pharmaceuticals gains Australian TGA approval for REDEMPLO (plozasiran), expanding global access for familial chylomicronemia syndrome patients.
Genprex Receives Israel Patent for Reqorsa Gene Therapy Combined with PD-1 Antibodies in Cancer Treatment
Genprex secures Israeli patent protection for Reqorsa gene therapy combination with PD-1 antibodies, strengthening intellectual property portfolio for cancer treatment.
Vivacta Bio Raises $50M+ Series A Funding for GT801 CAR-T Gene Therapy Development
Vivacta Biotechnology closes $50M+ Series A funding to advance GT801, an innovative in vivo CAR-T therapy for blood cancers and autoimmune diseases.
Argo Biopharma Doses First Patient in Phase I Trial of siRNA Therapy BW-50218 for TTR-Related Disease
Argo Biopharma begins Phase I clinical trial of BW-50218, an siRNA therapeutic targeting transthyretin protein for rare disease treatment in Australia.
Anixa Biosciences Lira-cel CAR-T Therapy Shows Positive Survival Data in Ovarian Cancer Phase 1 Trial
Anixa Biosciences announces positive survival data for Lira-cel CAR-T therapy in ovarian cancer Phase 1 trial, with presentation at ISCT 2026 meeting.
Andelyn Biosciences Partners with ENCell to Expand Gene Therapy Manufacturing in Asia-Pacific
Andelyn Biosciences and ENCell form strategic partnership to enhance global gene therapy manufacturing capabilities and expand access to treatments.
Rznomics RZ-001 Shows 61.5% Response Rate in Hepatocellular Carcinoma Trial at AACR 2026
Rznomics reports encouraging interim data for RZ-001 RNA editing therapy in liver cancer, showing 61.5% response rate with favorable safety profile at AACR 2026.
Argo Biopharma Begins Phase II Trials of BW-40202 siRNA Therapy for Rare Kidney Diseases
Argo Biopharma doses first patients in Phase II trials of BW-40202, an investigational siRNA therapy targeting complement factor B for PNH and IgAN treatment.
Gene Expression Analysis Market Reaches $5.93 Billion by 2031, Driving Drug Discovery Innovation
Gene expression analysis market projected to grow from $4.23B in 2026 to $5.93B by 2031 at 7.0% CAGR, led by drug discovery applications.